Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). - Wikidata - awgldk - TriplyDB

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

http://www.wikidata.org/entity/Q33988780

about

What is the best way to measure renal fibrosis?: A pathologist’s perspective Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry disease Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up Dysregulated autophagy contributes to podocyte damage in Fabry's disease.Update on role of agalsidase alfa in management of Fabry disease.Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Epithelial-Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010 Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.Agalsidase benefits renal histology in young patients with Fabry disease.Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease Fibrosis: a key feature of Fabry disease with potential therapeutic implications Renal complications of Fabry disease in children Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease Lysosome dysfunction in the pathogenesis of kidney diseases.Fabry's disease: an example of cardiorenal syndrome type 5.Early Renal Involvement in a Girl with Classic Fabry Disease.Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment.Pathomechanisms of renal Fabry disease.Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.Coexistence of Fabry disease and IgA nephropathy: a report of two cases.Immunohistochemical diagnosis of Fabry nephropathy and localisation of globotriaosylceramide deposits in paraffin-embedded kidney tissue sections.Medullary thick ascending limb impairment in the GlatmTg(CAG-A4GALT) Fabry model mice.Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.Fabry disease Urine-derived cells: a promising diagnostic tool in Fabry disease patients

P2860

Q26796641-DC69B2E3-8015-479F-A69A-7307C00097F6 Q33645550-C382C4EE-9D5F-4B7A-87BA-67753B6EAC61 Q33667541-D3E259DE-8E17-4B0B-8C42-662BDD2ACB57 Q33683158-34DFD059-5894-4C1C-AB53-5D9CE979DE14 Q34360126-7031AC58-F044-46B1-8E73-A74834110CA4 Q34560209-87624160-1E1B-4FF6-9D02-4E2406D769CF Q34730562-451ECE25-EDD2-4883-84B4-928BC800CDB3 Q34883178-9A96DA9A-96C8-43FD-8A7E-EEB8B08A5233 Q35587768-29729753-94BB-47A6-8969-F03AF9898791 Q35751224-7DA49A19-DDB3-49CA-B169-EE182D5CA734 Q35788989-19DB7F52-8FA9-4359-862B-9F7BA6793A93 Q35990846-447F2EA7-5AF6-46AF-BBF3-99D47C47ECDE Q36089921-91D53C6C-7EC8-4264-897C-8C0E2F0014EB Q36294339-8802EF77-0716-49E9-B64D-E1D75342E2A6 Q36475780-1928BAF4-9A2E-4399-A7B4-ED51FB1EE2EE Q36509288-82867753-7921-4A16-B1DB-13B71E595931 Q36808226-AB9D9D8B-AA09-4148-9FA6-12A5E0DA995B Q37113004-0BD5F4DE-9A3C-4787-B65D-65388B7AC453 Q37265117-17497971-1202-4868-992B-1C335C99B97D Q37624954-2B82D417-BBDD-4B50-B108-503783682F8B Q38161818-7D2C2B3C-B733-4204-B9AB-A5F5938CA2FF Q38558725-2E4BB9E3-0C1E-44FF-BF6A-A68582B434C5 Q44049056-D0C77413-B225-44B9-872C-3E18A3D1B91D Q47144777-9E66B178-3063-4B25-B2FD-36599C1A586E Q48287690-F5481B69-5136-46A9-94C5-C3F6D197FEE2 Q48632125-624F46E6-ED5B-49C2-AFBE-CA0AB5BE9801 Q50426715-760018F1-F49E-4980-864B-CC6E7FED35D6 Q51372656-D6F6D9FF-3C23-4B0E-A976-126C1D24D5DA Q52725758-A9D749F2-AD2C-4FB4-8DAA-1EF174866887 Q52872249-708AD7A5-9459-4584-9342-4B4B882B9012 Q53099040-CA609743-1E8E-45AE-B327-2E9E9AD55BEC Q56905945-E6B42B22-E021-4821-9658-0DB06AA3F414 Q57175109-D2D6AF79-710D-4F21-89D0-0BD0B0C65FC2

P2860

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

http://www.wikidata.org/entity/Q33988780

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Scoring system for renal patho ...... of Fabry Nephropathy (ISGFN).

@ast

Scoring system for renal patho ...... of Fabry Nephropathy (ISGFN).

@en

type

label

Scoring system for renal patho ...... of Fabry Nephropathy (ISGFN).

@ast

Scoring system for renal patho ...... of Fabry Nephropathy (ISGFN).

@en

prefLabel

Scoring system for renal patho ...... of Fabry Nephropathy (ISGFN).

@ast

Scoring system for renal patho ...... of Fabry Nephropathy (ISGFN).

@en

P1433

Q33988780-2932FDB0-FDF8-4A9C-B4D7-D332EDEF74A6

P1476

Q33988780-6CFDCE36-1A28-4E26-9D5F-62FE4B3017CB

P2093

Q33988780-04459424-91B5-4098-A429-ACA31269DC6F

Q33988780-0E380022-CCE1-4F9E-8EB5-FA5E3EBFA16D

Q33988780-1453D15B-109A-4938-8C52-C09E41563609

Q33988780-1757F211-5EE7-48C3-8A58-7B0B39BCDDB8

Q33988780-183534D9-1027-4352-A37F-644206795F73

Q33988780-1EC1D5D0-F5FF-48CD-8859-69DE040E5A75

Q33988780-24DA3B7E-10F3-470D-92D5-C605651723D8

Q33988780-2CBE79EC-D889-4DF4-B63D-D9E8476849A9

Q33988780-4B6568F5-7800-4417-8390-C7AAB8384E61

Q33988780-5A861391-BF93-4773-BB4F-24A70C1C593A

P2860

Q33988780-02163D5A-617C-4DB0-815C-5D3C7A9D8602

Q33988780-040F97B6-B70F-4B38-B4AF-976542222A9B

Q33988780-1090C6BE-4CAA-417C-9407-E2A1AB3A988C

Q33988780-1522B6B1-F61A-4C5C-BAE0-0D2BE9B67920

Q33988780-1CF89012-5AD0-4401-AD32-1F44F73E4764

Q33988780-24054F6C-6301-481E-8410-5D025719F440

Q33988780-29A2F321-E9E2-4A54-86DA-76974E9977C2

Q33988780-3626C182-E592-4380-81BD-DA3575FE582C

Q33988780-3D5ECA62-D971-4526-83C5-C5F9183EBF0A

Q33988780-3D6A13E0-CEF7-49B0-9E89-6F43D9C2F81E

P304

Q33988780-410C0F4D-C422-40C0-87D6-E7D471A84700

P31

Q33988780-1D1DEF30-A0AF-4399-B2F9-376597DFAA68

P356

Q33988780-040C07B6-D2D6-43A5-9F47-35E28F83311B

P407

Q33988780-3E7C842E-D584-4F20-AFC6-038E238B5743

P433

Q33988780-8B250CC2-4045-451B-B7ED-E24EB5B2AFDB

P478

Q33988780-B41DCDAD-1377-4F14-AFF3-58151F92832C

P577

Q33988780-09139E36-55E4-4420-B883-550D566A0C7A

P5875

Q33988780-20867DF0-97EC-4E07-8281-C87721D2F356

P698

Q33988780-D09D0989-1D30-4BCA-A869-DA50C65822DB

P932

Q33988780-A941BC97-CE08-4015-B0FF-936C3CE1E155

P356

P1433

Nephrology Dialysis Transplantation

P1476

Scoring system for renal patho ...... of Fabry Nephropathy (ISGFN).

@en

P2093

Agnes B Fogo

http://www.w3.org/2001/XMLSchema#string

Aine Burns

http://www.w3.org/2001/XMLSchema#string

Alexander J Howie

http://www.w3.org/2001/XMLSchema#string

Bojan Vujkovac

http://www.w3.org/2001/XMLSchema#string

Carmen Valbuena

http://www.w3.org/2001/XMLSchema#string

David G Warnock

http://www.w3.org/2001/XMLSchema#string

Dusan Ferluga

http://www.w3.org/2001/XMLSchema#string

Einar Svarstad

http://www.w3.org/2001/XMLSchema#string

Federic Barbey

http://www.w3.org/2001/XMLSchema#string

Frank Breunig

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease

Statistical methods for assessing agreement between two methods of clinical measurement

Intraclass correlations: uses in assessing rater reliability

A method to quantify mouse coat-color proportions.

Renal pathological changes in Fabry disease.

Assessing kidney function--measured and estimated glomerular filtration rate.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

International IgA nephropathy network clinico-pathological classification of IgA nephropathy.

Renal ultrastructural findings in Anderson-Fabry disease.

Renal pathology in Fabry disease.

P304

2168-2177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFP528

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38014939

http://www.w3.org/2001/XMLSchema#string

P698

19833663

http://www.w3.org/2001/XMLSchema#string

P932

2902894

http://www.w3.org/2001/XMLSchema#string